阿扎胞苷联合或不联合艾曲泊帕一线治疗伴血小板减少的中危或高危骨髓增生异常综合征
SUPPORT 是一项 3 期随机双盲安慰剂对照研究,纳入基线血小板 <75×10^9/L 的 IPSS 中危-1、中危-2 或高危 MDS 患者,1:1 随机接受艾曲泊帕或安慰剂联合阿扎胞苷治疗。主要终点为第 1 至 4 周期无需血小板输注的患者比例。因疗效跨越预设无效阈值及安全性原因,研究提前终止;艾曲泊帕组主要终点达成比例低于安慰剂组(16% vs 31%),总体反应率亦较低(20% vs 35%),且无生存获益。
要点
- 艾曲泊帕联合阿扎胞苷组第 1 至 4 周期无需血小板输注比例低于安慰剂组(16% vs 31%)。
- 研究者评估的总体反应率艾曲泊帕组低于安慰剂组(20% vs 35%)。
- 两组任何系血液学改善均无差异,总体生存和无进展生存均无改善。
核心结论
- 与单用阿扎胞苷相比,艾曲泊帕联合阿扎胞苷加重血小板恢复,反应率更低,并有向急性髓系白血病进展增加的趋势。
研究设计与样本
- SUPPORT 为 3 期随机双盲安慰剂对照研究,纳入 IPSS 中危-1、中危-2 或高危且基线血小板 <75×10^9/L 的 MDS 患者。
- 患者 1:1 随机接受艾曲泊帕(起始 200 mg/d,东亚人 100 mg/d;最大 300 mg/d,东亚人 150 mg/d)或安慰剂,联合阿扎胞苷(75 mg/m2 皮下注射,每日一次,每 28 天用 7 天)。
主要发现
- 终止时,艾曲泊帕组 28/179(16%)与安慰剂组 55/177(31%)患者达到主要终点(第 1 至 4 周期无需血小板输注)。
- 研究者评估的总体反应(国际工作组标准;完全、骨髓或部分反应)在艾曲泊帕组和安慰剂组分别为 20% 和 35%。
- 两组任何系血液学改善均无差异,总体生存和无进展生存均无改善。
- 艾曲泊帕组 vs 安慰剂组发生率 ≥10% 的不良事件为发热性中性粒细胞减少和腹泻。
- 基于计划中期分析,独立数据监测委员会因疗效结局跨越预设无效阈值及安全性原因建议提前终止研究。
局限性
- 基于计划中期分析,独立数据监测委员会因疗效结局跨越预设无效阈值及安全性原因建议提前终止研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline platelets <75 × 109/L were randomized 1:1 to eltrombopag (start, 200 mg/d [East Asians, 100 mg/d], maximum, 300 mg/d [East Asians, 150 mg/d]) or placebo, plus azacitidine (75 mg/m2 subcutaneously once daily for 7 days every 28 days). The primary end point was the proportion of patients platelet transfusion-free during cycles 1 through 4 of azacitidine therapy. Based on planned interim analyses, an independent data monitoring committee recommended stopping the study prematurely because efficacy outcomes crossed the predefined futility threshold and for safety reasons. At termination, 28/179 (16%) eltrombopag and 55/177 (31%) placebo patients met the primary end point. Overall response (International Working Group criteria; complete, marrow, or partial response) occurred in 20% and 35% of eltrombopag and placebo patients, respectively, by investigator assessment. There was no difference in hematologic improvement in any cell lineage between the 2 arms. There was no improvement in overall or progression-free survival. Adverse events with ≥10% occurrence in the eltrombopag vs placebo arm were febrile neutropenia and diarrhea. Compared with azacitidine alone, eltrombopag plus azacitidine worsened platelet recovery, with lower response rates and a trend toward increased progression to acute myeloid leukemia. This trial was registered at www.clinicaltrials.gov as #NCT02158936.
引用
- Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018. PMID: 30305280. doi:10.1182/blood-2018-06-855221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。